

Cytovia Therapeutics, Inc. and STC Biologics, Inc. enter into a partnership to develop and manufacture NK cell engager multi-specific antibodies

Newton, MA and New York, NY, January 2nd, 2020 – Cytovia Therapeutics, Inc. a biopharmaceutical company focused on the development of Natural Killer (NK) therapeutics, and STC Biologics, Inc., a process development and GMP biomanufacturing company, announced today that they have entered into a strategic partnership to develop novel multi-specific antibodies targeting NK cell engagers and specific antigens for the treatment of hematological and solid tumors.

Dr. Daniel Teper, CEO of Cytovia said: “Cytovia is committed to advancing the development of NK engager multi-specific antibodies, an alternative to T-cell engagers and CAR-T cell therapy in the treatment of cancer. The partnership with STC Biologics, Inc. leverages their expertise and capabilities to accelerate the progress of therapeutic candidates toward clinical trial initiation.”

Dr Magdalena Leszczyniecka, President and CEO of STC Biologics, Inc added: “We are very excited to help Cytovia to advance their novel therapies towards clinical development. This new format for multi-specific antibodies should reduce the manufacturability hurdles seen before with other bispecific formats and allow us to expedite the development using platform antibody methods.”

Professor Armand Bensussan, Director of INSERM Immuno-oncology unit at Hospital Saint Louis in Paris and a scientific advisor to Cytovia commented: “NK cells play a major role in the first-line immune defense against cancer. Cytovia has identified novel NK engager targets and benefits from a flexible plug and play multi-specific antibody.”

About Cytovia Therapeutics: Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies. Lean more at cytoviatx.com.

About STC Biologics: STC Biologics, Inc. is a boutique biologics CDMO located in Newton, MA that providing full CMC development and consulting to enable its partners advance their biologic products from discovery to commercial approval. STC Biologics was founded in 2009 and its team brings expertise and track record in biologics drug development from global biopharmaceutical companies. The cross-training of its scientists in diverse fields with integration of biology into CMC development is what makes STC Biologics unique in its ability to expedite timelines to the clinic. STC Biologics strives to realize "Speed to Clinic" through integrated product development, technical rigor, and flexibility.

For more information, please contact anna@cytoviatx.com or magda@stcbiologics.com